Collegium Pharmaceutical Stock News

Collegium Pharmaceutical Inc (NASDAQ:COLL) – Equities researchers at Jefferies Financial Group cut their Q1 2020 earnings estimates for Collegium Pharmaceutical in a research note issued to investor

It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...

COVID-19 means Pain Therapeutics Conference is Remote

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Seattle Genetics (SGEN), Minerva Neurosciences (NERV) and

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Seattle Genetics ( SGEN – Research Report ), Minerva Neurosciences ( NERV – Research Report ) and O

Needham analyst Serge Belanger maintained a Buy rating on Collegium Pharmaceutical (COLL) today and set a price target of $38.00. The company's shares

Needham analyst Serge Belanger maintained a Buy rating on Collegium Pharmaceutical (COLL – Research Report) today and set a price

Credit Suisse AG increased its stake in Collegium Pharmaceutical Inc (NASDAQ:COLL) by 54.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exch

Top Ranked Growth Stocks to Buy for April 1st

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 1st

Collegium Pharmaceutical Inc (NASDAQ:COLL) saw a large increase in short interest in March. As of March 13th, there was short interest totalling 5,582,500 shares, an increase of 8.4% from the February

Collegium Pharmaceutical recently reported impressive Q4/2019 earnings with a beat on EPS and revenue. Xtampza ER continues to impress and is steadily moving cl

Wall Street analysts predict that Collegium Pharmaceutical Inc (NASDAQ:COLL) will report sales of $78.31 million for the current fiscal quarter, Zacks reports. Six analysts have made estimates for Col

After Wedbush and Needham gave Albireo Pharma (NASDAQ: ALBO) a Buy rating last month, the company received another Buy, this time from William Blair.

After Wedbush and Needham gave Albireo Pharma (NASDAQ: ALBO) a Buy rating last month, the company received another Buy, this